Background/objectives: Chronic lymphocytic leukemia (CLL) exhibits a heterogeneous clinical course influenced by genetic factors, such as the mutational status of immunoglobulin variable regions (IGHV). Recently, B-cell receptor (BcR) stereotypes have shown promising prognostic value, potentially surpassing IGHV status. The PAIS study analyzed BcR stereotypes and IGHV mutations in newly diagnosed Portuguese CLL...
The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in recent years and the attention given to the characteristics of patients have allowed the reduction of toxicities and increased survival and quality of life of patients with multiple myeloma. These tre...
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment. However, currently, the treatment-free remission concept is becoming an important goal in clinical practice, and several tyrosine kinase inhibitors discontinuation studies have shown that round 50% of patients with a durable deep molecular response beyond majo...
Multiple Myeloma (MM) accounts for approximately one percent of all cancers and is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Clinical features are anemia, bone pain, renal failure and hypercalcemia. Rarely, a bacterial infection is the initial presentation of this disease. We report a case in which bacteremia caused by Streptococcus pn...
β-Thalassemia is one of the most common hemoglobinopathies in the world, characterized by the absence or decrease on the β-hemoglobin chain production. The coexistence of β-Thalassemia and lymphoma is rare, but it has been reported in the literature, associated with better treatment approaches of β-Thalassemia major. In this article, it is reported a case of β-Thalassemia minor presented with non-Hodgkin lympho...